AdAlta Ltd. (AU:1AD) has released an update.
AdAlta Ltd has announced an investor update webinar, hosted by CEO Tim Oldham, to discuss new growth funding from New Life Sciences Capital and Meurs Group. The event aims to engage investors with the company’s advances in its proprietary i-body technology and upcoming Phase II clinical studies for their lead candidate, AD-214, to treat fibrotic diseases. Additionally, AdAlta is exploring partnerships to expand its i-body platform and pipeline, including CAR-T cell therapies and diagnostics.
For further insights into AU:1AD stock, check out TipRanks’ Stock Analysis page.
